SCHEMBL5435147

SCHEMBL5435147

COC(=O)c1cccc(N(C)S(C)(=O)=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
KMT2A Q03164 5/20 0.55
ALDH1A1 P00352 5/20 0.55
MEN1 O00255 4/20 0.55
LMNA P02545 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
KDM4E B2RXH2 2/20 0.55
TSHR P16473 1/20 0.55
HSD17B10 Q99714 1/20 0.55
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.53
TP53 P04637 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 2/20 0.51
USP2 O75604 1/20 0.51
MAPK1 P28482 2/20 0.51
HTT P42858 2/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14536599 0.85 POLB (0.49) POLBKMT2AALDH1A1MEN1L3MBTL1
SCHEMBL4823244 0.84 GAA (0.53) ALDH1A1LMNATSHRRAB9ANPC1
SCHEMBL475760 0.83 KDM4E (0.56) POLBKMT2AALDH1A1MEN1LMNA
SCHEMBL1883657 0.82 KMT2A (0.55) POLBKMT2AALDH1A1MEN1LMNA
SCHEMBL30006467 0.82 LMNA (0.51) KMT2AALDH1A1MEN1LMNAL3MBTL1
SCHEMBL3855094 0.82 LMNA (0.51) KMT2AALDH1A1MEN1LMNAL3MBTL1
SCHEMBL5720754 0.82 POLB (0.52) POLBKMT2AALDH1A1MEN1KDM4E
SCHEMBL641703 0.82 KDM4E (0.58) POLBKMT2AALDH1A1LMNAL3MBTL1
SCHEMBL30444224 0.82 KDM4E (0.58) POLBKMT2AALDH1A1LMNAL3MBTL1
SCHEMBL1020560 0.80 L3MBTL1 (0.78) POLBKMT2AALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035313-A1 Compounds PFIZER INC. 2009-02-05 US disclosed
US-20090035313-A1 Compounds PFIZER INC. 2009-02-05 US disclosed
US-20070142386-A1 New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 ASTRAZENECA (SE) 2007-06-21 US disclosed
EP-1651641-B1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LTD (GB) 2007-05-23 EP disclosed
EP-1651640-B1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LTD (GB) 2007-02-14 EP disclosed
CN-1856499-A New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 ASTRAZENECA AB (SE) 2006-11-01 CN disclosed
EP-1675862-A1 NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO 4,5-D PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 AstraZeneca AB (SE) 2006-07-05 EP disclosed
WO-2005033115-A1 NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO[4,5-D] PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 ASTRAZENECA AB (SE) 2005-04-14 WO disclosed
WO-2005009995-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142386-A1 New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 CX3CR1, CCR2, CXCR4 POLB 2926/4885KMT2A 4262/4885ALDH1A1 3396/4885
US-20090035313-A1 Compounds NQO1, NAMPT, NNT POLB 1310/4885KMT2A 2721/4885ALDH1A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.